Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717289 | 0.88 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2ATSHRP2RY14 | |
| SCHEMBL4716827 | 0.83 | PDGFRB (0.55) | MEN1KMT2AP2RY14MAPK8MAPK9 | |
| SCHEMBL4718231 | 0.83 | ANO1 (0.48) | LMNAMAP2K7CSF1RP2RX4ANO1 | |
| SCHEMBL4716848 | 0.83 | LMNA (0.59) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4718487 | 0.81 | TP53 (0.54) | SMN1; SMN2MEN1KMT2ATSHRMAPT | |
| SCHEMBL5253161 | 0.79 | LMNA (0.54) | SMN1; SMN2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4719226 | 0.78 | KDR (0.58) | SMN1; SMN2MEN1KMT2ATSHRLMNA | |
| SCHEMBL4717679 | 0.77 | MEN1 (0.57) | SMN1; SMN2MEN1KMT2ATSHRKDM4E | |
| SCHEMBL4719248 | 0.77 | PTPN11 (0.50) | SMN1; SMN2MEN1KMT2AMAPK9CSF1R | |
| SCHEMBL4717158 | 0.76 | NLRP3 (0.56) | MEN1KMT2AP2RY14LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | claimed |
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| CN-1917880-A | Pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1737462-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | SMN1; SMN2 3049/4885MEN1 1106/4885KMT2A 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.